CRMI

China Regenerative Medicine International Limited (CRMI) is a high-tech enterprise specializing in the research, production, and sales of tissue engineering and regenerative medicine products. It was listed on the Hong Kong Stock Exchange on July 18, 2001 (Stock Code: 8158.HK). The company's business spans five major sectors: tissue engineering, cosmetics, cell storage, preparation and treatment, group hospital management, and the group’s overseas division. Headquartered in Hong Kong, CRMI has seven modern R&D centers and production bases in Xi'an, Shenzhen, Suzhou, Tianjin, Changzhou, and Hong Kong. It has grown into a leading enterprise in China’s tissue engineering and regenerative medicine fields. Upholding the philosophy of "For the Future, Create Regeneration," China Regenerative Medicine Group continuously explores new frontiers in human life sciences. The group has undertaken several major national scientific research projects, including the "863" and "973" programs, and has won multiple awards, such as the "First Prize of National Science and Technology Progress Award." Its tissue-engineered skin product "Antifu," which is the only one in China with active cells, solidifies the group's leadership position in the field of tissue engineering and regenerative medicine in China. The bioengineered cornea "Aixintong" is the world's first marketed bioengineered cornea, ushering in a new era of corneal transplantation and placing China at the forefront of global research in regenerative medicine for corneal diseases.